We need to find biomarkers for prognostic, diagnostic and personalised treatment development. Notably to fight cancers that affect tissues. Since biopsies are invasive, it’s better to look for biomarkers in body fluids. Indeed, a simple blood sample becomes a kind of ‘liquid biopsy’ to reveal tissues affections. For 13 years, increasing interest has been shown for miRNA as biomarkers and it will last for sure. The 2 main reasons are that they are major regulators of cell processes and they are released from tissues into the blood. They are major biomarker candidates in serum and plasma. Thus, these circulating miRNA (cmiRNA) are the best hope for modern medicine. Still, a lot of research has to be done to determine the specific signature for each pathology, and also depending on the patient background. Obviously, cmiRNA profiling is a key step and requires sensitive and reproducible method. Sequencing, qRT-PCR, several kind of microarrays… Let’s explore together what the best approach could be. [Read more…]
Recently, tebu-bio and Toray reached agreement for miRNA and mRNA profiling lab services. Already recognised as a European service provider in genomics, proteomics and cell-based assays, tebu-bio now brings European researchers access to Toray’s 3D-Gene® microRNA and mRNA profiling technology, offered through lab services.
During recent lab collaboration sessions, Toray’s 3D-gene® experts and tebu-bio’s lab staff shared their experiences and skills regarding miR and mRNA profiling technologies. A nice opportunity for me to ask Hideo Akiyama, PhD (Deputy General Manager – New Projects Development Division at Toray Industries, Inc.) 3 questions regarding the power of this “3D-gene® black resin” for microarray analysis.